Skip to main content

Table 3 Incidence rates of tuberculosis and herpes per 100 patient-years in controlled and cumulative periods

From: Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data

 

Controlled periods

Cumulative periods

Outcome

Abatacept: n = 2653; py = 2357

Placebo: n = 1485; py = 1254

Abatacept: n = 7044; py = 21,274

n (%)

IR/100 py (95% CI)

n (%)

IR/100 py (95% CI)

n (%)

IR/100 py (95% CI)

Tuberculosis (overall)

1 (< 0.1)

0.04 (0–0.2)

1 (< 0.1)

0.08 (0–0.4)

13 (0.2)

0.06 (0.03–0.10)

 Pulmonary tuberculosis

0

0

0

0

6 (0.1)

0.03 (0.01–0.06)

 Lymph node tuberculosis

0

0

0

0

2 (< 0.1)

0.01 (0–0.03)

 Tuberculosis (unspecified)

1 (< 0.1)

0.04 (0.0–0.2)

1 (0.1)

0.08 (0.0–0.4)

2 (< 0.1)

0.01 (0–0.03)

 Bone tuberculosis

0

0

0

0

1 (< 0.1)

0.01 (0–0.03)

 Peritoneal tuberculosis

0

0

0

0

1 (< 0.1)

0.01 (0–0.03)

 Tuberculous pleurisy

0

0

0

0

1 (< 0.1)

0.01 (0–0.03)

 Herpes simplex

57 (2.1)

2.5 (1.9–3.2)

22 (1.5)

1.8 (1.1–2.7)

60 (0.9)

1.48 (1.32–1.65)

 Herpes zoster

44 (1.7)

1.9 (1.4–2.5)

21 (1.4)

1.7 (1.1–2.6)

284 (4.0)

1.53 (1.36–1.71)

 Herpes virus infection (NOS)

5 (0.2)

0.2 (0.1–0.5)

4 (0.3)

0.3 (0.1–0.8)

20 (0.3)

0.09 (0.06–0.15)

  1. CI confidence interval, IR incidence rate, NOS not otherwise specified, py patient-years